Site Group Page (References Reporting High Throughput Detection Method)
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Site Group Page (References Reporting High Throughput Detection Method)
 

Site Information
SOGA2 (human) S1421-p EDVTPPLsPDDLKYI 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 23, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40
SOGA2 iso4 (human) S427-p EDVTPPLsPDDLKYI
SOGA2 (mouse) S1407-p EDVTPPLsPDDLKYI 1, 21, 24
SOGA2 (rat) S1522-p EDVTPPLsPDDLKYI

References

1

Trinidad JC, et al. (2012) Global identification and characterization of both O-GlcNAcylation and phosphorylation at the murine synapse. Mol Cell Proteomics 11, 215-29
22645316   Curated Info

2

Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70
22496350   Curated Info

3

(2011) CST Curation Set: 12647; Year: 2011; SILAC: N; Biosample/Treatment: MKN-45(cell line)/untreated; Disease: gastric carcinoma; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) Antibody Used to Purify Peptides prior to MS2: T*PP Motif (T*PP) (D61C3) Rabbit mAb Cat#: 5757, PTMScan(R) T*PP Motif (T*PP) Immunoaffinity Beads Cat#: 5758
Curated Info

4

(2011) CST Curation Set: 12863; Year: 2011; SILAC: N; Biosample/Treatment: MKN-45(cell line)/untreated; Disease: gastric carcinoma; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) Antibody Used to Purify Peptides prior to MS2: T*PP Motif (T*PP) (D61C3) Rabbit mAb Cat#: 5757, PTMScan(R) T*PP Motif (T*PP) Immunoaffinity Beads Cat#: 5758
Curated Info

5

(2011) CST Curation Set: 12864; Year: 2011; SILAC: N; Biosample/Treatment: MKN-45(cell line)/untreated; Disease: gastric carcinoma; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) Antibody Used to Purify Peptides prior to MS2: T*PP Motif (T*PP) (D61C3) Rabbit mAb Cat#: 5757, PTMScan(R) T*PP Motif (T*PP) Immunoaffinity Beads Cat#: 5758
Curated Info

6

(2011) CST Curation Set: 12865; Year: 2011; SILAC: N; Biosample/Treatment: MKN-45(cell line)/untreated; Disease: gastric carcinoma; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) Antibody Used to Purify Peptides prior to MS2: T*PP Motif (T*PP) (D61C3) Rabbit mAb Cat#: 5757, PTMScan(R) T*PP Motif (T*PP) Immunoaffinity Beads Cat#: 5758
Curated Info

7

(2011) CST Curation Set: 12640; Year: 2011; SILAC: N; Biosample/Treatment: Jurkat(cell line)/calyculin & pervanadate; Disease: T cell leukemia; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

8

(2011) CST Curation Set: 12641; Year: 2011; SILAC: N; Biosample/Treatment: Jurkat(cell line)/calyculin & pervanadate; Disease: T cell leukemia; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

9

(2011) CST Curation Set: 12642; Year: 2011; SILAC: N; Biosample/Treatment: Jurkat(cell line)/calyculin & pervanadate; Disease: T cell leukemia; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

10

(2011) CST Curation Set: 12552; Year: 2011; SILAC: N; Biosample/Treatment: Jurkat(cell line)/calyculin & pervanadate; Disease: T cell leukemia; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

11

(2011) CST Curation Set: 12440; Year: 2011; SILAC: N; Biosample/Treatment: Jurkat(cell line)/calyculin & pervanadate; Disease: T cell leukemia; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

12

(2011) CST Curation Set: 12442; Year: 2011; SILAC: N; Biosample/Treatment: Jurkat(cell line)/calyculin & pervanadate; Disease: T cell leukemia; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

13

(2011) CST Curation Set: 12443; Year: 2011; SILAC: N; Biosample/Treatment: Jurkat(cell line)/calyculin & pervanadate; Disease: T cell leukemia; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

14

(2011) CST Curation Set: 12381; Year: 2011; SILAC: N; Biosample/Treatment: MKN-45(cell line)/untreated; Disease: gastric carcinoma; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995
Curated Info

15

(2011) CST Curation Set: 12382; Year: 2011; SILAC: N; Biosample/Treatment: MKN-45(cell line)/untreated; Disease: gastric carcinoma; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995
Curated Info

16

(2011) CST Curation Set: 12383; Year: 2011; SILAC: N; Biosample/Treatment: MKN-45(cell line)/untreated; Disease: gastric carcinoma; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995
Curated Info

17

(2011) CST Curation Set: 12384; Year: 2011; SILAC: N; Biosample/Treatment: MKN-45(cell line)/untreated; Disease: gastric carcinoma; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995
Curated Info

18

(2011) CST Curation Set: 12385; Year: 2011; SILAC: N; Biosample/Treatment: MKN-45(cell line)/untreated; Disease: gastric carcinoma; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995
Curated Info

19

(2011) CST Curation Set: 12386; Year: 2011; SILAC: N; Biosample/Treatment: MKN-45(cell line)/untreated; Disease: gastric carcinoma; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995
Curated Info

20

(2011) CST Curation Set: 12018; Year: 2011; SILAC: N; Biosample/Treatment: Jurkat(cell line)/calyculin & pervanadate; Disease: T cell leukemia; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

21

Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22
21659604   Curated Info

22

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

23

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

24

Huttlin EL, et al. (2010) A tissue-specific atlas of mouse protein phosphorylation and expression. Cell 143, 1174-89
21183079   Curated Info

25

(2010) CST Curation Set: 10710; Year: 2010; SILAC: N; Biosample/Treatment: HeLa(cell line)/untreated; Disease: cervical adenocarcinoma; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996
Curated Info

26

(2010) CST Curation Set: 10711; Year: 2010; SILAC: N; Biosample/Treatment: HeLa(cell line)/nocodazole; Disease: cervical adenocarcinoma; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996
Curated Info

27

(2010) CST Curation Set: 10689; Year: 2010; SILAC: N; Biosample/Treatment: HeLa(cell line)/nocodazole; Disease: cervical adenocarcinoma; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996
Curated Info

28

(2010) CST Curation Set: 10686; Year: 2010; SILAC: N; Biosample/Treatment: HeLa(cell line)/untreated; Disease: cervical adenocarcinoma; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996
Curated Info

29

(2010) CST Curation Set: 9968; Year: 2010; SILAC: N; Biosample/Treatment: 293(cell line)/untreated; Disease: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Millipore 05-368
Curated Info

30

(2010) CST Curation Set: 9969; Year: 2010; SILAC: N; Biosample/Treatment: 293(cell line)/Insulin; Disease: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Millipore 05-368
Curated Info

31

(2010) CST Curation Set: 9974; Year: 2010; SILAC: N; Biosample/Treatment: 293(cell line)/rapamycin; Disease: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Millipore 05-368
Curated Info

32

Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53
20363803   Curated Info

33

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

34

(2009) CST Curation Set: 7398; Year: 2009; SILAC: N; Biosample/Treatment: NCI-H2228(cell line)/untreated; Disease: non-small cell lung cancer; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation)
Curated Info

35

(2009) CST Curation Set: 7397; Year: 2009; SILAC: N; Biosample/Treatment: NCI-H2228(cell line)/untreated; Disease: non-small cell lung cancer; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation)
Curated Info

36

Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46
19690332   Curated Info

37

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

38

Olsen JV, et al. (2006) Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 127, 635-48
17081983   Curated Info

39

Beausoleil SA, et al. (2006) A probability-based approach for high-throughput protein phosphorylation analysis and site localization. Nat Biotechnol 24, 1285-92
16964243   Curated Info

40

Nousiainen M, et al. (2006) Phosphoproteome analysis of the human mitotic spindle. Proc Natl Acad Sci U S A 103, 5391-6
16565220   Curated Info

Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.